FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161437581> ?p ?o ?g. }

• W2161437581 endingPage "S164" @default.
• W2161437581 startingPage "S164" @default.
• W2161437581 abstract "RationalePatients with severe combined immunodeficiency (SCID) who acquire parainfluenza type 3 (PI3) respiratory infections may not clear these potentially fatal infections. We report the successful use of ribavirin in 2 patients with SCID for PI3 before immune reconstitution.ResultsRibavirin is a nucleoside antimetabolite antiviral drug with activity against several DNA and RNA viruses.Patient 1 was a 3-month-old male who presented with PI3 and Pneumocystis carinii pneumonia (PCP). Immune evaluation demonstrated IL2RG SCID. He was treated with ribavirin for the PI3 infection, and trimethoprim-sulfamethoxazole for PCP. The patient's respiratory status normalized with subsequent negative respiratory viral cultures and discontinuation of the ribavirin. The patient redeveloped cough and tachypnea along with positive PI3 on respiratory viral cultures and the ribavirin restarted. His respiratory status improved again, and the ribavirin was continued until successful bone marrow transplant from an HLA matched sibling. The ribavirin was then discontinued with subsequent negative respiratory viral cultures.Patient 2 was a 5-month-old female who presented with pneumonia with growth of Klebsiella pneumoniae, Pseudomonas aeruginosa, adenovirus (AV), and PI3 from a BALF and CMV retinitis. Immune evaluation showed RAG1 SCID. She was treated with IVIG, ceftazidime, tobramycin, gancyclovir, fluconazole, and trimethoprim-sulfamethoxazole. Ribavirin was given and stopped after 5 weeks with negative viral cultures for both AV and PI3. AV and PI3 were subsequently again isolated and ribavirin was again given until successful umbilical cord transplantation was done.ConclusionsWe report two SCID patients treated successfully with long-term ribavirin until immune reconstitution. RationalePatients with severe combined immunodeficiency (SCID) who acquire parainfluenza type 3 (PI3) respiratory infections may not clear these potentially fatal infections. We report the successful use of ribavirin in 2 patients with SCID for PI3 before immune reconstitution. Patients with severe combined immunodeficiency (SCID) who acquire parainfluenza type 3 (PI3) respiratory infections may not clear these potentially fatal infections. We report the successful use of ribavirin in 2 patients with SCID for PI3 before immune reconstitution. ResultsRibavirin is a nucleoside antimetabolite antiviral drug with activity against several DNA and RNA viruses.Patient 1 was a 3-month-old male who presented with PI3 and Pneumocystis carinii pneumonia (PCP). Immune evaluation demonstrated IL2RG SCID. He was treated with ribavirin for the PI3 infection, and trimethoprim-sulfamethoxazole for PCP. The patient's respiratory status normalized with subsequent negative respiratory viral cultures and discontinuation of the ribavirin. The patient redeveloped cough and tachypnea along with positive PI3 on respiratory viral cultures and the ribavirin restarted. His respiratory status improved again, and the ribavirin was continued until successful bone marrow transplant from an HLA matched sibling. The ribavirin was then discontinued with subsequent negative respiratory viral cultures.Patient 2 was a 5-month-old female who presented with pneumonia with growth of Klebsiella pneumoniae, Pseudomonas aeruginosa, adenovirus (AV), and PI3 from a BALF and CMV retinitis. Immune evaluation showed RAG1 SCID. She was treated with IVIG, ceftazidime, tobramycin, gancyclovir, fluconazole, and trimethoprim-sulfamethoxazole. Ribavirin was given and stopped after 5 weeks with negative viral cultures for both AV and PI3. AV and PI3 were subsequently again isolated and ribavirin was again given until successful umbilical cord transplantation was done. Ribavirin is a nucleoside antimetabolite antiviral drug with activity against several DNA and RNA viruses. Patient 1 was a 3-month-old male who presented with PI3 and Pneumocystis carinii pneumonia (PCP). Immune evaluation demonstrated IL2RG SCID. He was treated with ribavirin for the PI3 infection, and trimethoprim-sulfamethoxazole for PCP. The patient's respiratory status normalized with subsequent negative respiratory viral cultures and discontinuation of the ribavirin. The patient redeveloped cough and tachypnea along with positive PI3 on respiratory viral cultures and the ribavirin restarted. His respiratory status improved again, and the ribavirin was continued until successful bone marrow transplant from an HLA matched sibling. The ribavirin was then discontinued with subsequent negative respiratory viral cultures. Patient 2 was a 5-month-old female who presented with pneumonia with growth of Klebsiella pneumoniae, Pseudomonas aeruginosa, adenovirus (AV), and PI3 from a BALF and CMV retinitis. Immune evaluation showed RAG1 SCID. She was treated with IVIG, ceftazidime, tobramycin, gancyclovir, fluconazole, and trimethoprim-sulfamethoxazole. Ribavirin was given and stopped after 5 weeks with negative viral cultures for both AV and PI3. AV and PI3 were subsequently again isolated and ribavirin was again given until successful umbilical cord transplantation was done. ConclusionsWe report two SCID patients treated successfully with long-term ribavirin until immune reconstitution. We report two SCID patients treated successfully with long-term ribavirin until immune reconstitution." @default.
• W2161437581 created "2016-06-24" @default.
• W2161437581 creator A5020868962 @default.
• W2161437581 creator A5088614636 @default.
• W2161437581 date "2008-02-01" @default.
• W2161437581 modified "2023-09-27" @default.
• W2161437581 title "Two patients with SCID and Parainfluenza Type 3 Respiratory Infections Treated with Long Term Nebulized Ribavirin before Immune Reconstitution" @default.
• W2161437581 doi "https://doi.org/10.1016/j.jaci.2007.12.603" @default.
• W2161437581 hasPublicationYear "2008" @default.
• W2161437581 type Work @default.
• W2161437581 sameAs 2161437581 @default.
• W2161437581 citedByCount "0" @default.
• W2161437581 crossrefType "journal-article" @default.
• W2161437581 hasAuthorship W2161437581A5020868962 @default.
• W2161437581 hasAuthorship W2161437581A5088614636 @default.
• W2161437581 hasBestOaLocation W21614375811 @default.
• W2161437581 hasConcept C126322002 @default.
• W2161437581 hasConcept C159047783 @default.
• W2161437581 hasConcept C203014093 @default.
• W2161437581 hasConcept C2522874641 @default.
• W2161437581 hasConcept C2776408679 @default.
• W2161437581 hasConcept C2777914695 @default.
• W2161437581 hasConcept C2780040827 @default.
• W2161437581 hasConcept C2993183539 @default.
• W2161437581 hasConcept C534529494 @default.
• W2161437581 hasConcept C71924100 @default.
• W2161437581 hasConceptScore W2161437581C126322002 @default.
• W2161437581 hasConceptScore W2161437581C159047783 @default.
• W2161437581 hasConceptScore W2161437581C203014093 @default.
• W2161437581 hasConceptScore W2161437581C2522874641 @default.
• W2161437581 hasConceptScore W2161437581C2776408679 @default.
• W2161437581 hasConceptScore W2161437581C2777914695 @default.
• W2161437581 hasConceptScore W2161437581C2780040827 @default.
• W2161437581 hasConceptScore W2161437581C2993183539 @default.
• W2161437581 hasConceptScore W2161437581C534529494 @default.
• W2161437581 hasConceptScore W2161437581C71924100 @default.
• W2161437581 hasIssue "2" @default.
• W2161437581 hasLocation W21614375811 @default.
• W2161437581 hasOpenAccess W2161437581 @default.
• W2161437581 hasPrimaryLocation W21614375811 @default.
• W2161437581 hasRelatedWork W2046281956 @default.
• W2161437581 hasRelatedWork W2161437581 @default.
• W2161437581 hasRelatedWork W2351075441 @default.
• W2161437581 hasRelatedWork W2362648266 @default.
• W2161437581 hasRelatedWork W2373375513 @default.
• W2161437581 hasRelatedWork W2379765656 @default.
• W2161437581 hasRelatedWork W2383408750 @default.
• W2161437581 hasRelatedWork W2387482266 @default.
• W2161437581 hasRelatedWork W2392318222 @default.
• W2161437581 hasRelatedWork W2625168965 @default.
• W2161437581 hasVolume "121" @default.
• W2161437581 isParatext "false" @default.
• W2161437581 isRetracted "false" @default.
• W2161437581 magId "2161437581" @default.
• W2161437581 workType "article" @default.